Summary. -Prophylaxis of Influenza A virus infections is based on the vaccines inducing antibodies to the major viral antigens, hemagglutinin (HA) and neuraminidase (NA). Since these antigens continuously change during virus replication in various hosts, only the currently circulating strains should be used in the vaccines. Besides, monitoring of the naturally occurring changes in HA, NA, and respective genes, especially those associated with resistance to the NA inhibitors is necessary. 
Introduction
Influenza A viruses cause moderate to severe illness and affect people of all ages. Hospitalization and deaths occur mainly in the high-risk groups (Keshtkar-Jahromi et al., 2008) . Annual epidemics cause millions cases of severe illness and hundred thousands deaths worldwide (Molinari et al., 2007) . The principal targets of the protective immune response against influenza viruses are two major surface glycoproteins HA and NA. Combination of antibodies against these major viral antigens of the circulating strain offers optimal protection against influenza illness (Powers et al., 1996) .
In the viral life cycle, NA has enzymatic activity that cleaves sialic acid from complex carbohydrate molecules (receptors), prevents self-aggregation, and facilitates release of virions from the infected cells. It also enables the virus to penetrate mucosal secretion to reach target cells of the respiratory tract (Colman et al., 1994) . Immunity induced by NA can reduce the severity and duration of the illness by reduction of the virus replication, which is a reasonable goal in the event of influenza pandemic (Gillim-Ross et al., 2007; Richard et al., 2008; Aoki et al., 2009) .
HA and NA genes change periodically due to the sequential evolution in immune or partially immune populations (Munoz et al., 2005) . Two important means for the protection and treatment of influenza infection are the vaccination and antiviral drugs. Due to the continuous changes of HA and NA genes, vaccine strains must be selected annually based on the surveillance of influenza viruses circulating in humans. Antiviral drugs, especially NA inhibitors, are the valuable addition to the options used to control the influenza infection ((Moscona et al., 2005; Sheu et al., 2008) .
Recent increase in circulating influenza mutants resistant to the NA inhibitors demands a precise surveillance of NA inhibitor-resistant viruses in different countries (Aeron et al., 2009; Cheng et al., 2009) .
In this study, NA genes of 30 Iranian isolates of the influenza H1N1 virus from seasons 2005-2009 were sequenced and compared to the corresponding vaccine strains. NA sequences were subjected to the sequence and phylogenetic analyses with emphasis on the mutation conferring resistance to the NA inhibitors.
Materials and Methods
Clinical samples. The specimens were sent to the National Influenza Centre at School of Public Health of Tehran University from various regions of Iran. Samples were collected in duplicates. One tube was stored at -70°C and the other one was used for screening of the influenza virus A/H1N1 by real-time PCR .The positive samples were inoculated into Madin-Darby Canine Kidney cells (MDCK) for virus isolation. Altogether 30 H1N1 isolates from five recent influenza seasons (2004-2005, 2005-2006, 2006-2007, 2007-2008, and 2008-2009) were available for sequencing. The numbers, names, abbreviations of isolates and Acc. Nos. of their NA complete gene sequences in GeneBank are presented in Table 1 .
RT-PCR. RNA was extracted from 150 μl of each cell culture supernatants with NucleoSpin ® RNA virus extraction kit (Machery-Nagel Company). cDNAs were synthesized using the M-MLV reverse transcriptase and random hexamer primers. The full length NA gene amplification was carried out using two following sets of forward and reverse primers (designed at NIMR, London,UK) to amplify two overlapping fragments. Set one -N1F1: 5΄-AGC AGG AGT TTA AAA TGA ATC CAA-3΄and N1R1: 5΄-TCT AAG TCT GTT ACT TTT AGT CCT-3΄. Set two -N1F2: 5΄-ATA ATG ACC GAT GGC CCG AGT AAT-3΄ and N1R2: 5΄-GTA GAA ACA AGG AGT TTT TTC AAC-3΄. The resulting amplicons were sequenced.
Sequence and phylogenetic analyses. Sequences were analyzed with BioEdit version 7.0.0 DNA analysis software (Hall, 1999) . Phylogenetic tree was constructed using treecon package version 1.3 b (Van de Peer and De Wachter, 1997) applying Kimura's twoparameter method and the neighbor-joining method with bootstrap analysis (1000 replicates). 
Results and Discussion
In this study, NA genes of 30 Iranian seasonal influenza A/H1N1 isolates collected from February 2005 to January 2009 were completely sequenced. Molecular and phylogenetic analysis was performed to reveal their molecular changes and phylogenetic relationships to the vaccine strains and to investigate NA inhibitor-resistant mutants. Numbering of the isolates was based on N1 gene.
Phylogenetic analysis
Genetic relationships of the NA gene of Iranian isolates with vaccine and reference strains were constructed by neighbor-joining analysis with 1000 bootstrapped replicates. The result showed a continuous evolution of the influenza isolates. The collected isolates were relevant to their vaccine strains except for the isolates collected in the season 2007-08, which showed a higher nucleotide variation. In accordance with the branching of phylogenetic tree, the collected isolates were divided into two groups A, B, and two subgroups BI, BII. These four sets were concurrent with the influenza seasons (Fig. 1) .
The 
Sequence analyses
The amino acid analysis showed conserved residues in both catalytic sites (R118, D151, R152, R225, E277, R293, R368, Y402) and framework sites supporting the catalytic residues (E119, R156, W179, S180, D199, I223, E228, H275, E278, N295, E425) for all isolates except H275Y in 2008-2009 isolates (Chutinimitkul et al., 2007; Richard et al., 2008) . Viruses in comparison to their corresponding vaccine strains altered amino acids at the antigenic sites (A-C) (Munoz et al., 2005) , phylogenetically important regions (PIR) (A-O) and some other residues (Fanning et al., 2000; Bragstad et al., 2008) .
In comparison to the strain A/New Caledonia/20/ 99(H1N1) recommended as a vaccine strain for Northern hemisphere for the seasons 2000-2001 to 2006-2007, all eighteen isolates collected in 2004-2005, 2005-2006, and 2006-2007 showed the mutations E332K at antigenic site C, V48I at PIR-B, and N450D. Besides, the strain Ir/153/06 had the mutation H45N at PIR-B and K78E at PIR-C that are typical of Brisbane/59/2007-like viruses. Furthermore, the mutation S35N was seen in the only isolate collected in the season . For all 2007 isolates, there were found 16 amino acid changes compared to the strain This study showed that the trend of variation in NA gene of H1N1 isolates was going up. Among viruses from five recent flu seasons amino acids substitutions in 2007-08 isolates could have altered antibody binding properties, since epidemiologically important drift variants have four or more amino acids substitutions located in more than one antigenic site (Hata et al., 2006) Resistance to NA inhibitors NA inhibitors (zanamivir and oseltamivir) are effective antiviral drugs for the influenza prophylaxis and treatment. The most common genetic indication of oseltamivir drug resistance in N1 is the mutation H275Y. This mutation occurs in or nearby the active site of the enzyme and it was expected that mutant viruses would be less viable than sensitive ones (Dharan et al., 2009) .
Until recently, the circulating viruses had shown only low prevalence of NA inhibitors resistance (<1%) (Monto et al., 2006; Dharan et al., 2009) . Before the season 2007-2008, the resistant viruses containing the H275Y mutation had been described only in association with the NA inhibitors exposure (Monto et al., 2006) . However, recent surveillance revealed a significant number of circulating A/H1N1 influenza strains with the H275Y mutation (Aeron et al., 2009) . It is possible that the resistant viruses may have acquired other mutations that compensate these changes in NA gene, so the virus is allowed to continue with the efficient replication and transmission (Helenius et al., 2004; Richard et al., 2008; Cheng et al., 2009) .
Analysis of H1N1 viruses in Europe revealed that the overall frequency of H1N1 resistant strains was 25% (Lackenby et al., 2008) . In the USA, the resistance to oseltamivir was identified in 98.5% of H1N1 viruses (Dharan et al., 2009) .
In South Africa, all tested influenza isolates contained the H275Y mutation. Furthermore, these viruses had one or two mutations (M23L and N73K) in the stalk region indicating that some genetic drifts of N1 from the older strains had occurred (Besselaar et al., 2008) .
In the present study, all isolates collected from 2005 to 2009 were investigated for the mutation H275Y and for other molecular markers of NA drug resistance: D79G, H126N, S247N, and G249R mutations. The mutation H275Y was found just in all tested isolates of the season 2008-2009 and moreover, one of them had the mutation N73K in stalk region that was found also in African H1N1 viruses (Besselaar et al., 2008) .
None of the isolates had a molecular marker of NA drug resistance at the other positions like D79G, H126N, S247N, and G249R.
Glycosylation sites
The specific sequence for N-linked glycosylation is defined as N-X-S/T, where X can be any amino acid except proline or aspartic acid (Helenius et al., 2004) . N-linked glycosylation facilitates the folding, stability, solubility, transportation, 
Ag B, C = antigenic site; PIR B, C, F = phylogenetically important region.
antigenicity, and immunogenicity of the protein (Chutinimitkul et al., 2007) . Eight potential glycosylation sites in the NA molecule at the positions 44, 58, 63, 70, 88,146, 235, and 434 (Bragstad et al., 2008) and one additional site in the position 455 have been conserved since 2005 with some exceptions. The additional glycosylation site was created by the S35N mutation in strain Ir/670/07 and in contrast, the H45P substitution eliminated a glycosylation site in strain Ir/147/05.
